| Description | Mitolactol is an alkylating antineoplastic toxic to bone marrow; utilized in breast cancer, also in combination with other drugs. Mitolactol is able to cross bloodbrain barrier, consequently could control certain brain tumors. |
| Synonyms | NSC 104800, NSC-104800, NSC104800 |
| molecular weight | 307.96 |
| Molecular formula | C6H12Br2O4 |
| CAS | 10318-26-0 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Jeney A, Kralovánszky J, Lapis K. [Anticancer drug research in Hungary, 1950-2000]. Magy Onkol. 2017 Dec 18;61(4):375-382. Epub 2017 Nov 30. Hungarian. PubMed PMID: 29257158. 2. Qi L, Ding L, Wang S, Zhong Y, Zhao D, Gao L, Wang W, Lv P, Xu Y, Wang S. A network meta-analysis: the overall and progression-free survival of glioma patients treated by different chemotherapeutic interventions combined with radiation therapy (RT). Oncotarget. 2016 Oct 18;7(42):69002-69013. doi: 10.18632/oncotarget.10763. PubMed PMID: 27458167; PubMed Central PMCID: PMC5356607. 3. Ishiyama T, Jinguu A, Matsumoto H, Kikuchi J, Suzuki T, Yamakawa M. [A case of adult primitive neuroectodermal tumor(PNET)with multiple lung metastases effectively treated with ADM, IFM(AI)regimen]. Gan To Kagaku Ryoho. 2012 Aug;39(8):1287-9. Japanese. PubMed PMID: 22902461. 4. Olasz L, Orsi E, Markó T, Szalma J. Induction chemotherapy response and recurrence rates in correlation with N0 or N+ stage in oral squamous cell cancer (OSCC). Cancer Metastasis Rev. 2010 Dec;29(4):607-11. doi: 10.1007/s10555-010-9259-7. Review. PubMed PMID: 20842409. |